ACO E-bulletin, October 2015. Images not displaying below? Enjoy this online
Ce courriel ne s’affiche pas correctement? Affichez-le dans votre navigateur
logo
Canadian HIV Vaccine Initiative (CHVI)
Research and Development
Alliance Coordinating Office (ACO)

alliance-aco.ca

October 2015

  About   Partners   Contact   Français
 


Congratulations, Dr. Mark Wainberg!
2016 Inductee into the Canadian Medical Hall of Fame

Dr. Wainberg


The ACO would like to congratulate Dr. Mark Wainberg who has been selected for induction into The Canadian Medical Hall of Fame (CMHF).

Dr. Wainberg has made multiple contributions to the field of HIV drug resistance. He was the first researcher to show that subtype differences among HIV strains could result in differing profiles of mutations responsible for drug resistance. Although his laboratory continues to work in the field of drug development and drug resistance, more recently he has also turned his attention to novel concepts in the prevention of HIV infection in developing countries.

He is the primary investigator of one of five team research projects funded by the Canadian HIV Vaccine Initiative (CHVI) through the HIV/AIDS Vaccine Discovery and Social Research Team Grants under the Canadian Institute of Health Research (CIHR), in partnership with the Department of Foreign Affairs Trade and Development (DFATD). The aim of this grant titled "The Botswana-Canada AIDS Vaccine Discovery Partnership" is the discovery and characterization of highly potent and broadly neutralizing antibodies that target the HIV virus using innovative immunologic techniques and cutting edge technologies.

READ MORE


Luca Melnychuk video




We would like to thank everyone who participated in the ACO Evaluation Survey. Our survey winner is Thibault Mesplede from the McGill University AIDS Centre, Montreal, QC. Thank you and congratulations, Thibault!

Upcoming Events

CLINICAL TRIALS 101: INDUSTRY V ACADEMIA & NAVIGATING REGULATORY REQUIREMENTS

Webinar - Thursday, November 12, 2015, 1:00 – 2:30 pm EST

Please join us for a webinar entitled "Clinical Trials 101: Industry V Academia & Navigating Regulatory Requirements" presented by Nathalie Beliveau, Chief Clinical Research Officer and Dana Nohynek, Director of Regulatory Affairs and Quality Assurance at the Providence Health Care Research Institute. MORE INFORMATION

CAREER PATHWAYS FOR BIOMEDICAL SCIENTISTS

New and Early Career Investigator Workshop – Thursday, February 4 to Friday, February 5, 2016 | Toronto, Ontario

The ACO is now accepting applications for the New and Early Career Investigator Workshop entitled Career Pathways for Biomedical Scientists. The aim of this workshop is to identify various career pathways and options for new and early career investigators with an interest in HIV vaccine research and development. The workshop will also identify gaps in training to help prepare for non-academic career paths and to provide networking opportunities between new and early career investigators and industry representatives. MORE INFORMATION

Trainees interested in attending the workshop should apply here by December 10, 2015. You will be notified of your acceptance to the workshop by December 15, 2015.

New Research

A Higher Frequency of NKG2A+ than of NKG2A- NK Cells Responds to Autologous HIV-Infected CD4 Cells irrespective of Whether or Not they Coexpress KIR3DL1.

J Virol. 2015 Oct 1;89(19):9909-19. Doi: 10.1128/JVI.01546-15. Epub 2015 Jul 22.
Lisovsky I, Isitman G, Song R, DaFonseca S, Tremblay-McLean A, Lebouché B, Routy JP, Bruneau J, Bernard NF

Epidemiological and functional studies implicate NK cells in HIV control. However, there is little information available on which NK cell populations, as defined by the inhibitory NK cell receptors (iNKRs) they express, respond to autologous HIV-infected CD4(+) (iCD4) T cells. NK cells acquire antiviral functions through education, which requires signals received from iNKRs, such as NKG2A and KIR3DL1 (here, 3DL1), engaging their ligands. READ MORE

Differential Ability of Primary HIV-1 Nef Isolates To Downregulate HIV-1 Entry Receptors.

J Virol. 2015 Sep 15;89(18):9639-52. Doi: 10.1128/JVI.01248-15. Epub 2015 Jul 15.
Toyoda M, Ogata Y, Mahiti M, Maeda Y, Kuang XT, Miura T, Jessen H, Walker BD, Brockman MA, Brumme ZL, Ueno T

HIV-1 Nef downregulates the viral entry receptor CD4 as well as the coreceptors CCR5 and CXCR4 from the surface of HIV-infected cells, and this leads to promotion of viral replication through superinfection resistance and other mechanisms. Nef sequence motifs that modulate these functions have been identified via in vitro mutagenesis with laboratory HIV-1 strains. However, it remains unclear whether the same motifs contribute to Nef activity in patient-derived sequences and whether these motifs may differ in Nef sequences isolated at different infection stages and/or from patients with different disease phenotypes. READ MORE


Resources

Canadian HIV Vaccine Initiative (CHVI) Interactive Projects Map

The CHVI's Interactive Projects Map highlights recipients of CHVI funding around the world and visual guide to some of Canada's contribution to HIV/AIDS research. TRY THE MAP to find out where Canadian HIV vaccine research is taking place.

network


Funding Opportunities

Canadian Institutes of Health Research

Application Deadline: 2015-12-15
The CIHR HIV/AIDS Research Initiative and its partners have developed an Implementation Science initiative in order to address the gap that exists in the application of evidence into health policy and programs. The goal of the initiative is to reduce the incidence of HIV, Hep C (HCV) and other sexually transmitted and blood-borne infections (STBBIs) within and across key populations in Canada.

Two complementary funding opportunities have been developed within the framework of the initiative:
Component 1 – Adaptation Grants: will support the development of multi-sectoral teams, identification of promising or effective interventions and the development of multi-faceted programs through intervention adaptation.
Component 2 – Implementation Grants: will support multi-sectoral teams in multi-year investigations of program implementation and scale-up across multiple heterogeneous communities.

This funding opportunity will support Component 1 – Adaptation Grants. It is anticipated that a funding opportunity for Component 2 – Implementation Grants – will be launched in 2016 in order to support the transition of Component 1 projects into longer-term implementation studies. Teams will not be required to hold Component 1 grants to be eligible for the Component 2 funding opportunity. Teams that are ready to investigate the scale-up of a multi-faceted prevention program may apply directly to Component 2 when it is launched. LEARN MORE

There will be a webinar on Friday, October 30th from 12:30pm-2:00pm EST to discuss the recently launched funding opportunity. Please register for the webinar online

Please feel free to contact the CIHR HIV/AIDS Research Initiative (HIVAIDS-VIHSIDA@cihr-irsc.gc.ca) for more information.

View all current opportunities

Conferences

November 29 to December 4, 2015
International Conference on AIDS & STI in Africa (ICASA)
Harare, Zimbabwe

November 30 to December 2, 2015
3rd International Conference on HIV/AIDS, STDs & STIs
Atlanta, USA

February 22 to 25 2016
Conference on Retroviruses and Opportunistic Infections (CROI) 2016
Boston, USA

March 20 to 24, 2016
Keystone Symposia – HIV Persistence: Pathogenesis and Eradication (X7)
California, USA

March 20 to 24, 2016
Keystone Symposia – HIV Vaccines (X8)
California, USA

May 12 to 15 2016
CAHR 2016
Winnipeg, Canada

See full list of conferences

 



You are receiving this email because you registered to receive news updates from the Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office (ACO) or you are a member of a CHVI-funded
project team.


Annual Update

  Annual Update

The Annual Report offers highlights of ACO activities over the past fiscal year. Read our 2014-2015 Annual Update.



White Paper

whitepapers

The ACO has developed a White Paper to foster effective coordination of key players across the Canadian HIV vaccine research landscape.

About Us

The CHVI Research and Development Alliance Coordinating Office (ACO) was established by the Government of Canada and the Bill & Melinda Gates Foundation in November 2011 at the International Centre for Infectious Diseases (ICID), a
not-for-profit,
non-governmental organization based in Winnipeg.

Address

ALLIANCE COORDINATING
OFFICE (ACO)
International Centre for Infectious Diseases
515 Portage Avenue
Winnipeg, MB, Canada
R3B 2E9
Tel.: 204 946 0908
Fax: 204 946 0927
email:
aco@icid.com

 

Follow Us:

facebook

Facebook

twitter Twitter
share Share with
colleagues
email us Email us
 
 
 
 
 

Production of this newsletter has been made possible through a financial contribution from the Public Health Agency of Canada. The views expressed herein do not necessarily represent the views of the Public Health Agency of Canada.

Third-Party E-bulletin Disclaimer
This E-Bulletin contains links to third party websites ("Linked Sites"), which are not under the control of ACO and ACO is not responsible for the contents of any Linked Site, including any link contained in a Linked Site or any changes or updates to a Linked Site. The Linked Sites may not be available in French or English. ACO is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement by ACO of the Linked Site or any association with its operators. We do not guarantee the accuracy of any information accessed through or published or provided by the Linked Site. You are responsible for viewing and abiding by the privacy statements and terms of use posted at the Linked Sites. Any specific comments or inquiries regarding the Linked Sites should be directed to the operator of the Linked Site.


Copyright © 2015
Canadian HIV Vaccine Initiative Research and Development Alliance Coordinating Office

Update Subscription Preferences

Privacy Policy

Unsubscribe

Subscribe

Send to a Friend

 
eNewsletter powered by eTouchServices

The ACO E-Bulletin is deployed on behalf of the ACO by eTouchServices Inc..
162-2025 Corydon Ave. Suite 103 Winnipeg, MB R3P 0N5 Canada